GABY Inc. (GABLF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
GABY Inc. (GABLF) trades at $0.00 with AI Score 43/100 (Grade C). GABY Inc. operates in the cannabis industry, focusing on the production, marketing, and retail of cannabis-related consumer packaged goods in the United States. Market cap: $2.66M, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for GABLF: GABLF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates GABLF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
GABLF: the 1 perspectives are evenly split.
How is this calculated? →GABY Inc. (GABLF) Healthcare & Pipeline Overview
GABY Inc. is a cannabis-focused consumer packaged goods company operating in the U.S., offering a range of cannabis products under various brands. With a negative P/E ratio and profit margin, the company faces challenges in a competitive market while striving to expand its brand presence and market share.
What Is the Investment Thesis for GABLF?
Investing in GABY Inc. (GABLF) presents a high-risk, high-reward scenario. The company operates in the burgeoning U.S. cannabis market, which offers significant growth potential. However, GABLF's negative P/E ratio of -0.04 and a substantial negative profit margin of -134.4% indicate significant financial challenges. A gross margin of 46.3% suggests potential for profitability if operational efficiencies can be improved. The company's beta of 1.44 indicates higher volatility compared to the market. Growth catalysts include expansion into new states and increased brand recognition. Investors should closely monitor GABLF's ability to achieve profitability and manage its operating expenses.
Based on FMP financials and quantitative analysis
GABLF Key Highlights
- Market Cap of $2.66M indicates a micro-cap company with limited resources and higher risk.
- P/E Ratio of -0.04 reflects the company's current unprofitability.
- Profit Margin of -134.4% highlights significant operational inefficiencies and challenges in achieving profitability.
- Gross Margin of 46.3% suggests potential for profitability if operating expenses are managed effectively.
- Beta of 1.44 indicates higher volatility compared to the overall market, making it a riskier investment.
Who Are GABLF's Competitors?
GABLF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ATAI Atai Beckley NV is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders. The company | $4.88 | -5.97% | $1.80B | 68 |
| MEDS TRxADE HEALTH, Inc. | $7.59 | +4.55% | $13.28M | 63 |
| ONC BeOne Medicines Ltd. | $309.46 | +3.97% | $33.07B | 61 |
| NEUP Neuphoria Therapeutics Inc. | $3.44 | +1.78% | $18.59M | 60 |
| YI 111, Inc. | $4.13 | -0.12% | $36.04M | 44 |
| ALBHF Alibaba Health Information Technology Limited | $0.42 | +2.44% | $6.77B | 45 |
| WBA Walgreens Boots Alliance operates as a pharmacy-led health and beauty retail company with a global presence. The company | $11.98 | +0.50% | $10.37B | 45 |
| IPXL Impax Laboratories, Inc. | $18.30 | +0.55% | 46 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GABLF's Key Strengths?
- Established brands in key markets.
- Vertical integration provides control over the supply chain.
- Diverse product portfolio caters to various consumer preferences.
- Experienced management team with industry expertise.
What Are GABLF's Weaknesses?
- Negative profitability and high operating expenses.
- Limited financial resources compared to larger competitors.
- Dependence on regulatory approvals and changes in cannabis laws.
- Concentration of operations in a few key states.
What Could Drive GABLF Stock Higher?
- Potential for new state legalization of cannabis, expanding GABY Inc.'s market reach.
- Increasing consumer acceptance of cannabis products, driving demand for GABY Inc.'s offerings.
- Expansion of GABY Inc.'s distribution network through partnerships and acquisitions.
What Are the Key Risks for GABLF?
- Financial-distress signal — its Altman Z-Score of -8.99 sits in the distress zone (elevated bankruptcy risk).
- Regulatory changes and increased taxes could negatively impact GABY Inc.'s profitability.
- Intense competition from other cannabis companies.
- Fluctuations in cannabis prices and supply.
- Negative public perception and social stigma associated with cannabis.
What Are the Growth Opportunities for GABLF?
- Expansion into New States: GABY Inc. has the opportunity to expand its operations into new states as cannabis legalization continues to spread across the U.S. Entering new markets would allow the company to increase its revenue base and reach a wider customer audience. The timeline for this growth opportunity depends on the pace of legalization in different states, but it could potentially contribute significantly to revenue growth within the next 3-5 years. This expansion requires significant capital investment and regulatory compliance expertise.
- Increased Brand Recognition: GABY Inc. can invest in marketing and branding initiatives to increase brand awareness and loyalty among consumers. Building strong brands like Mankind, Kind Republic, Lulu's, 2Rise, and Dank Space can help the company differentiate its products from competitors and command premium pricing. This growth opportunity can be realized through targeted advertising campaigns, social media marketing, and partnerships with influencers. The timeline for achieving significant brand recognition is approximately 2-3 years.
- Development of New Products: GABY Inc. can develop and launch new cannabis-infused products to cater to evolving consumer preferences and needs. This includes exploring new product formats, flavors, and formulations. Innovation in product development can help the company attract new customers and retain existing ones. The timeline for developing and launching new products is approximately 1-2 years, depending on the complexity of the product and regulatory requirements. Focus on health and wellness trends could unlock new market segments.
- Strategic Partnerships and Acquisitions: GABY Inc. can pursue strategic partnerships and acquisitions to expand its operations, gain access to new technologies, and increase its market share. Collaborating with other cannabis companies, retailers, or technology providers can create synergies and enhance the company's competitive position. The timeline for completing strategic partnerships and acquisitions varies depending on the specific opportunities, but it could potentially contribute to significant growth within the next 2-4 years. Synergies with established players are key.
- Focus on Edibles and Infused Products: The market for cannabis edibles and infused products is growing rapidly, driven by increasing consumer demand for alternative consumption methods. GABY Inc. can capitalize on this trend by expanding its portfolio of edibles, beverages, and other infused products. This includes developing new flavors, formulations, and packaging options to appeal to a wider range of consumers. The timeline for expanding its edibles and infused products portfolio is approximately 1-2 years, with potential for significant revenue growth in the near term.
What Opportunities Does GABLF Have?
- Expansion into new states and markets.
- Development of new and innovative cannabis products.
- Strategic partnerships and acquisitions to increase market share.
- Growth in the market for cannabis edibles and infused products.
What Threats Does GABLF Face?
- Intense competition from other cannabis companies.
- Changing regulations and potential for increased taxes.
- Fluctuations in cannabis prices and supply.
- Negative public perception and social stigma associated with cannabis.
What Are GABLF's Competitive Advantages?
- Established Brand Portfolio: GABY Inc. has developed a portfolio of recognizable brands, including Mankind, Kind Republic, Lulu's, 2Rise, and Dank Space.
- Vertical Integration: The company's vertical integration allows it to control the entire value chain, from cultivation to retail.
- Distribution Network: GABY Inc. has established a distribution network to reach consumers through its own dispensaries and partnerships with other retailers.
What Does GABLF Do?
GABY Inc., originally incorporated as Gabriella's Kitchen Inc. in 2003 and rebranded in September 2019, is a Canadian-based company that produces, markets, sells, and retails cannabis-related consumer packaged goods in the United States. The company's operations encompass the entire value chain, from cultivation and processing to retail distribution. GABY Inc. offers a diverse portfolio of cannabis products, including flowers, concentrates, pre-rolls, edibles, topicals, and tinctures, catering to a wide range of consumer preferences and needs. These products are marketed under several brand names, including Mankind, Kind Republic, Lulu's, 2Rise, and Dank Space, each targeting specific market segments and consumer demographics. The company aims to establish a strong brand presence and capture a significant share of the rapidly growing U.S. cannabis market. Headquartered in Calgary, Canada, GABY Inc. focuses on expanding its operations and distribution network across key U.S. states, leveraging its established brands and product portfolio to drive revenue growth and profitability.
What Products and Services Does GABLF Offer?
- Produces cannabis flowers, concentrates, and pre-rolls.
- Manufactures cannabis-infused edibles like gummies and chocolates.
- Creates topical cannabis products such as creams and lotions.
- Develops and sells cannabis tinctures and oils.
- Packages and markets cannabis products under multiple brands.
- Retails cannabis products through its own dispensaries and partnerships.
- Distributes cannabis products to other retailers in the United States.
How Does GABLF Make Money?
- Cultivates and processes cannabis to create a variety of products.
- Markets and sells these products directly to consumers through its retail locations.
- Distributes its branded products to other dispensaries and retailers.
- Generates revenue through the sale of cannabis products.
What Industry Does GABLF Operate In?
GABY Inc. operates within the rapidly expanding U.S. cannabis market, which is projected to reach billions of dollars in the coming years. The industry is characterized by increasing legalization, evolving regulations, and intense competition. GABY Inc. competes with numerous other cannabis companies, including both large multi-state operators and smaller regional players. The company's success depends on its ability to differentiate its products, build strong brands, and navigate the complex regulatory landscape. Market trends include increasing demand for cannabis-infused products, growing acceptance of cannabis for medical and recreational use, and the consolidation of the industry through mergers and acquisitions.
Who Are GABLF's Key Customers?
- Adults aged 21 and over who are legally allowed to purchase cannabis.
- Medical cannabis patients with qualifying conditions.
- Recreational cannabis users seeking various consumption methods.
- Consumers interested in cannabis-infused products for wellness purposes.
How GABY Inc. Is Valued
GABY Inc. carries a market capitalization of $2.66M, placing it in the micro-cap category. Relative to its peer group, GABLF's quantitative score of 43/100 is below the peer average of 59/100.
ROE 291%Key Financial Metrics
Return on equity for GABY Inc. stands at 290.9%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is 39.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.16 means current liabilities exceed short-term assets, a liquidity point worth watching.
F-Score 5/9Financial Health
GABY Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -8.99 places it in the distress zone, a signal of elevated financial risk.
GABLF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Established brands in key markets.
- Vertical integration provides control over the supply chain.
- Diverse product portfolio caters to various consumer preferences.
- Experienced management team with industry expertise.
Bear Case
- Negative profitability and high operating expenses.
- Limited financial resources compared to larger competitors.
- Dependence on regulatory approvals and changes in cannabis laws.
- Concentration of operations in a few key states.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
GABLF Latest News
No recent news available for GABLF.
GABLF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GABLF.
Price Targets
Wall Street price target analysis for GABLF.
GABLF MoonshotScore
What does this score mean?
The MoonshotScore rates GABLF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Simon Lileikis
CEO
Simon Lileikis is the CEO of GABY Inc. His background includes experience in the cannabis industry and a track record of building and scaling businesses. He has a strong understanding of the regulatory landscape and consumer trends in the cannabis market. Prior to joining GABY Inc., Lileikis held leadership positions in other cannabis companies, where he was responsible for driving revenue growth, expanding market share, and developing new products. His expertise in marketing, sales, and operations makes him well-suited to lead GABY Inc. through its next phase of growth.
Track Record: Under Simon Lileikis' leadership, GABY Inc. has focused on expanding its brand presence and product portfolio. He has overseen the launch of new cannabis products and the expansion of the company's distribution network. Lileikis has also been instrumental in navigating the complex regulatory environment and securing key partnerships. His strategic decisions have helped GABY Inc. to increase its revenue and market share in a competitive market.
GABLF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that GABY Inc. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies on this tier often have limited financial information available and may be subject to greater risks. Unlike NYSE or NASDAQ-listed companies, OTC Other firms face less stringent listing standards, resulting in increased information asymmetry and potential for speculative trading. This tier is often associated with penny stocks and companies with distressed financials.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Financial Disclosure: The lack of readily available financial information makes it difficult to assess the company's financial health.
- Low Liquidity: Limited trading volume and wide bid-ask spreads can result in price volatility and difficulty executing trades.
- Regulatory Uncertainty: The cannabis industry is subject to evolving regulations and potential changes in laws.
- Going Concern Risk: The company's negative profitability and high operating expenses raise concerns about its ability to continue as a going concern.
- Dilution Risk: The company may need to raise additional capital through equity offerings, which could dilute existing shareholders' ownership.
- Verify the company's legal standing and registration.
- Review available financial statements and assess the company's financial health.
- Research the company's management team and their experience.
- Understand the company's business model and competitive landscape.
- Assess the regulatory risks and potential impact on the company's operations.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- Established Brands: GABY Inc. has developed a portfolio of recognizable brands.
- Vertical Integration: The company's vertical integration provides control over the supply chain.
- Distribution Network: GABY Inc. has established a distribution network to reach consumers.
Common Questions About GABLF (Healthcare)
What does GABY Inc. do?
GABY Inc. is a cannabis company that cultivates, manufactures, and retails a variety of cannabis products, including flowers, concentrates, edibles, topicals, and tinctures. The company operates under several brands, such as Mankind, Kind Republic, Lulu's, 2Rise, and Dank Space, catering to different consumer segments. GABY Inc. focuses on the U.S. cannabis market, aiming to establish a strong brand presence and expand its distribution network. The company's vertical integration allows it to control the entire value chain, from cultivation to retail, providing a competitive advantage in the market.
What do analysts say about GABLF stock?
Analyst coverage of GABLF is limited due to its OTC listing and small market capitalization. However, analysts generally focus on the company's growth potential in the expanding U.S. cannabis market. Key valuation metrics include revenue growth, gross margin, and operating expenses. Analysts also consider the regulatory risks and competitive landscape when evaluating GABLF. The consensus view is that GABLF is a high-risk, high-reward investment, with significant upside potential if the company can execute its growth strategy and achieve profitability. Investors should conduct their own due diligence and consider their risk tolerance before investing in GABLF.
What are the main risks for GABLF?
GABLF faces several significant risks, including regulatory uncertainty, intense competition, and financial challenges. The cannabis industry is subject to evolving regulations, and changes in laws could negatively impact GABLF's operations and profitability. The company also faces intense competition from other cannabis companies, both large and small. GABLF's negative profitability and high operating expenses raise concerns about its ability to continue as a going concern. Additionally, the company's OTC listing and limited liquidity pose risks for investors. Investors should carefully consider these risks before investing in GABLF.
What are the key factors to evaluate for GABLF?
GABY Inc. (GABLF) holds an AI score of 43/100 (low). Not financial advice.
How frequently does GABLF data refresh on this page?
GABLF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven GABLF's recent stock price performance?
GABY Inc. (GABLF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established brands in key markets. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GABLF overvalued or undervalued right now?
Valuing GABY Inc. (GABLF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying GABLF?
Before investing in GABY Inc. (GABLF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on OTC-listed companies.
- Financial data may be outdated or incomplete.